Congratulations to Kevin Hay (Hay Lab) for receiving a Cell Therapy and Transplant Canada Hans Messner Award for his project entitled, “Cell-free DNA: A new biomarker in CAR-T cell therapy”.
The funds received from this award will support a correlative study on the clinical trial Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients with Relapsed/Refractory CD19 Positive Hematologic Malignancies, to examine circulating tumour DNA to identify novel factors associated with toxicity, response, and duration of response after CD19 CAR-T cell therapy. This work will prove to be essential for the development of safer, more effective future CAR-T cell therapies.